Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series
Authors:
- 19 June 2020
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (5) , 752-762
Abstract
Background X-linked chronic granulomatous disease (CGD) is a primary immunodeficiency caused by mutations in the CYBB gene (located on Xp21.1). Patients with large deletions on chromosome Xp21.1 can present with the McLeod phenotype and also Duchenne muscular dystrophy or retinitis pigmentosa. The objective of the present study was to describe a series of French patients with CGD and the McLeod phenotype. Methods We retrospectively collected data from the medical records of 8 patients with CGD and the McLeod phenotype registered at the French National Reference Center for blood types. Results The median age at diagnosis of CGD was 1.2 years, the median age at diagnosis of the McLeod phenotype was 4.5 years, and the median length of follow-up was 15.2 years. Four patients displayed allo-immunization, with anti-KEL20 and anti-XK1 (formerly known as anti-KL) antibodies. Five of the 6 patients with available blood smears had acanthocytosis. Neuropsychiatric, muscle-related, and ocular manifestations were present in 4, 2, and 1 of the patients, respectively. Three of the 4 patients having undergone allogeneic hematopoietic stem cell transplantation (HSCT) are alive. Overall, 5 patients are alive, and 3 are alive and well. Conclusion This is the largest yet descriptive study of a series of patients with X-linked CGD and the McLeod phenotype. Although this disease combination is rare, the timely, accurate diagnosis of the McLeod phenotype is critical because of the serious post-transfusion complications. However, HSCT can be considered in these patients.Keywords
This publication has 30 references indexed in Scilit:
- A Review of Chronic Granulomatous DiseaseAdvances in Therapy, 2017
- Chronic granulomatous disease: Clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patientsAmerican Journal of Hematology, 2016
- Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous diseaseJournal of Allergy and Clinical Immunology, 2014
- Chronic Granulomatous Disease: The European ExperiencePLOS ONE, 2009
- Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: An Italian multicenter studyClinical Immunology, 2008
- Posaconazole as Salvage Therapy in Patients with Chronic Granulomatous Disease and Invasive Filamentous Fungal InfectionClinical Infectious Diseases, 2005
- Itraconazole to Prevent Fungal Infections in Chronic Granulomatous DiseaseNew England Journal of Medicine, 2003
- Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous diseaseProceedings of the National Academy of Sciences, 1997
- Trimethoprim-Sulfamethoxazole Prophylaxis in the Management of Chronic Granulomatous DiseaseThe Journal of Infectious Diseases, 1990
- NADPH oxidase deficiency in X-linked chronic granulomatous disease.Journal of Clinical Investigation, 1975